I'm LongbridgeAI, I can summarize articles.On November 6th (Thursday), four new stocks were listed today, among which VIGONVITA (02630) opened with a rise of over 185%, trading at HKD 95, making it the only new stock among the four to rise in the dark market. Excluding fees, a single lot of 200 shares would yield a profit of HKD 12,326. The IPO results for VIGONVITA show that the public offering was oversubscribed by 6,237.42 times, with a subscription rate of 1.68% for one lot, and the international offering was oversubscribed by 15.87 times. VIGONVITA was established in 2013 and is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing small molecule drugs in its strategic therapeutic areas (namely, neuropsychiatry and reproductive health). The company has acquired and developed two core products, LV232 and TPN171. LV232 is a dual-target 5-hydroxytryptamine transporter/5-hydroxytryptamine 3 (5-HTT/5-HT3) receptor modulator for the treatment of major depressive disorder. TPN171 is a type 5 phosphodiesterase (PDE5) inhibitor for the treatment of erectile dysfunction (ED). The company also has four candidate drugs in clinical stages and three candidate drugs in preclinical stages. In addition to its innovative pipeline, the company is also advancing its generic drug pipeline, aiming to generate visible, recurring revenue streams and cash flow as a strategic supplement to its business, thereby enhancing overall resilience
On November 6th (Thursday), four new stocks were listed and rose, among which VIGONVITA-B (02630) opened with an increase of over 185%, trading at HKD 95, making it the only new stock among the four to rise in the dark market. Excluding fees, a single lot of 200 shares would yield a profit of HKD 12,326.
The IPO results for VIGONVITA-B showed that the public offering was oversubscribed by 6,237.42 times, with a 1.68% chance of winning a lot in the subscription. The international offering was oversubscribed by 15.87 times.
Founded in 2013, VIGONVITA-B is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing small molecule drugs in its strategic therapeutic areas (namely, neuropsychiatry and reproductive health). The company has acquired and developed two core products, LV232 and TPN171. LV232 is a dual-target 5-hydroxytryptamine transporter/5-hydroxytryptamine 3 (5-HTT/5-HT3) receptor modulator for the treatment of major depressive disorder. TPN171 is a type 5 phosphodiesterase (PDE5) inhibitor for the treatment of erectile dysfunction (ED). The company also has four candidate drugs in clinical stages and three candidate drugs in preclinical stages. In addition to its innovative pipeline, the company is advancing its generic drug pipeline to generate visible, recurring revenue streams and cash flow as a strategic supplement to its business, thereby enhancing overall resilience.
In 2023-2024, the company achieved revenues of approximately HKD 200 million and HKD 11.832 million, with the profit attributable to the company’s owners decreasing from HKD 12.089 million to a loss of approximately HKD 211 million. In the first four months of 2025, revenue was HKD 12.958 million, with a loss attributable to the company’s owners of approximately HKD 112 million.
XPeng (02026) opened at HKD 124, down over 10% from the listing price of HKD 139, resulting in a loss of HKD 1,500 for a single lot of 100 shares, excluding fees.
WERIDE-W (00800) opened at HKD 24.98, down nearly 8% from the listing price of HKD 27.1, resulting in a loss of HKD 212 for a single lot of 100 shares, excluding fees.
JOYSON ELEC (00699) opened at HKD 21.5, down over 2% from the listing price of HKD 22, resulting in a loss of HKD 250 for a single lot of 500 shares